Silencing of microRNAs in vivo with ‘antagomirs’

By J. Krützfeldt, Nikolaus Rajewsky, Ravi Braich, K. G. Rajeev, Thomas Tuschl, M. Manoharan, M. Stoffel. Nature, 2005

4,108 citations recorded by the source corpus.

Subfields: Cancer Research, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/efea205fa3ed70bf803e91938e1d98cae60b6c9f

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

In Molecular Biology

Citations in the corpus

Molecular distinction between physiological and pathological cardiac hypertrophy: experimental findings and therapeutic strategies. (2010, background): “These molecules have been shown to be effective in vivo, capable of passing through cellular membranes to inhibit miRNA action by sequestering it from its targets (Krutzfeldt et al., 2005).”
CREB up-regulates long non-coding RNA, HULC expression through interaction with microRNA-372 in liver cancer (2010, background): “These results indicated that HULC may act as endogenous sponge ‘antagomirs’ as described previously (33,34).”
Role of microRNAs in vascular diseases, inflammation, and angiogenesis. (2008, background): “One promising approach for initial animal experiments is the systemic application of antagomirs that are single-stranded RNA oligonucleotides complementary to specific miRNAs with chemical modification for stability and cholesterol conjugation for better delivery that are well suited to block miRNA ”
A double-negative feedback loop between ZEB1-SIP1 and the microRNA-200 family regulates epithelial-mesenchymal transition. (2008, background): “In this regard, manipulation of microRNAs has recently been shown to be readily achievable in vivo and holds exciting promise for potential therapeutic applications involving the miR-200 family (42, 43).”
Lost in translation: an assessment and perspective for computational microRNA target identification (2009, background): “Silencing of a miRNA can be accomplished by introducing chemically modified oligonucleotides perfectly complementary to the mature miRNA (Krutzfeldt et al., 2005) or by knocking down a miRNA gene.”
MicroRNAs in development and disease. (2011, background): “Likewise, injection of 2=-O-methyl, phosphorothioate, 5=-cholesterol-conjugated antisense miR-122 modified oligonucleotides “antagomirs,” effectively inhibited miR122 in the liver (320).”
Overview of MicroRNA Biogenesis, Mechanisms of Actions, and Circulation (2018, background): “However, this interaction destabilizes the association between AGO and the 3 end of the miRNA promoting its degradation (48, 49).”